Spots Global Cancer Trial Database for cutaneous squamous cell carcinoma
Every month we try and update this database with for cutaneous squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma | NCT01500954 | Cutaneous Squam... | 1 Year - | Ruhr University of Bochum | ||
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | NCT03889912 | Cutaneous Squam... Basal Cell Carc... | Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Treatment With Nab-paclitaxel in Cutaneous SCC | NCT02076243 | Cutaneous Squam... | nab-paclitaxel | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | NCT04502888 | Cutaneous Squam... Squamous Cell C... | Drug: SL-172154 | 18 Years - | Shattuck Labs, Inc. | |
| Cemiplimab/Peg-Interferon-α in Advanced CSCC | NCT05729139 | Cutaneous Squam... Squamous Cell C... Advanced Squamo... | Cemiplimab-Rwlc PEG-IFN alfa-2a | 18 Years - | Baptist Health South Florida | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Cutaneous Squamous Cell Carcinoma Staging Study | NCT05695222 | Cutaneous Squam... | This is not an ... | 18 Years - 120 Years | Queen Mary University of London | |
| Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | NCT04293679 | Bowen's Disease Cutaneous Squam... | STP705 | 18 Years - | Sirnaomics | |
| Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | NCT04242173 | Cutaneous Squam... Cutaneous Squam... | Cemiplimab-Rwlc | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| CemiplimAb Survivorship Epidemiology | NCT03836105 | Cutaneous Squam... Basal Cell Carc... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | NCT04664582 | Cutaneous Squam... Sentinel Lymph ... | Sentinel Lymph ... | 18 Years - | Jewish General Hospital | |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | NCT05888844 | Cutaneous Squam... | INCB099280 | 18 Years - | Incyte Corporation | |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | NCT06384820 | Cutaneous Squam... | cemiplimab fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | NCT04429542 | Head and Neck S... Squamous Cell C... Colorectal Canc... Squamous Cell C... EGFR Amplificat... Epithelial Ovar... Pancreas Cancer Cutaneous Squam... Head and Neck N... Carcinoma, Squa... Squamous Cell C... | BCA101 Pembrolizumab | 18 Years - | Bicara Therapeutics | |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | NCT04050436 | Cutaneous Squam... Advanced Cutane... Metastatic Cuta... | Cemiplimab RP1 | 18 Years - | Replimune Inc. | |
| New Strategies Against Cutaneous Squamous Cell Carcinoma | NCT02672254 | Cutaneous Squam... | Samples with 2 ... | - | Corporacion Parc Tauli | |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | NCT03524326 | Head and Neck S... Cutaneous Squam... Head and Neck C... Head and Neck C... | Lenvatinib Pill Lenvatinib Pill Lenvatinib Pill Cetuximab Lenvatinib Pill Lenvatinib Pill | - | Memorial Sloan Kettering Cancer Center | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| OCT and Invasion in Cutaneous Skin Lesions | NCT06014697 | Cutaneous Squam... Bowen's Disease Actinic Keratos... Keratosis, Acti... Diagnosis | Optical Coheren... Clinical assess... | - | Maastricht University Medical Center | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | NCT05482880 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer High-Risk Cance... Quality of Life Satisfaction, P... | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC | NCT06046625 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer Patient Satisfa... High-Risk Cance... Preference, Pat... Decision Making Interview | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| New Strategies Against Cutaneous Squamous Cell Carcinoma | NCT02672254 | Cutaneous Squam... | Samples with 2 ... | - | Corporacion Parc Tauli | |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | NCT05256381 | Non-Small Cell ... Colorectal Canc... Cutaneous Squam... Hepatocellular ... Castration-resi... Ovarian Cancer | Nanrilkefusp Al... Pembrolizumab | 18 Years - | Sotio Biotech Inc. | |
| A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | NCT03982212 | Cutaneous Squam... Squamous Cell C... Basal Cell Carc... | Copaxone | 18 Years - | University of Kansas Medical Center | |
| Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | NCT05108090 | Squamous Cell C... Nonmelanoma Ski... Cutaneous Squam... | sentinel lymph ... | 18 Years - | Indiana University | |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | NCT05565417 | Non Small Cell ... Head and Neck S... Triple Negative... Cutaneous Squam... Hormone Recepto... Small Bowel Can... Esophageal Canc... Colorectal Canc... Diffuse Large B... Hodgkin Lymphom... Burkitt Lymphom... Follicular Lymp... | IMT-009 Fruquintinib | 18 Years - | Immunitas Therapeutics | |
| Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma | NCT01500954 | Cutaneous Squam... | 1 Year - | Ruhr University of Bochum | ||
| Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | NCT03492489 | Cutaneous Squam... | cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | NCT04293679 | Bowen's Disease Cutaneous Squam... | STP705 | 18 Years - | Sirnaomics | |
| Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs | NCT06014619 | Skin Cancer Complication Complication of... Complication,Po... Recurrence Recurrent Disea... Cutaneous Squam... Basal Cell Carc... Lentigo Maligna Lentigo Maligna... | Mohs surgery Slow Mohs surge... | 16 Years - | Maastricht University Medical Center | |
| Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients With Advanced NMSC | NCT05741073 | Basal Cell Carc... Cutaneous Squam... | 18 Years - | EuMelaReg gGmbH | ||
| Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery | NCT04620200 | Cutaneous Squam... | Nivolumab Ipilimumab | 18 Years - | The Netherlands Cancer Institute | |
| FLASH Radiotherapy for Skin Cancer | NCT05724875 | Basal Cell Carc... Cutaneous Squam... | FLASH RT Conventional RT | 60 Years - | Centre Hospitalier Universitaire Vaudois | |
| Cutaneous Squamous Cell Carcinoma Staging Study | NCT05695222 | Cutaneous Squam... | This is not an ... | 18 Years - 120 Years | Queen Mary University of London | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | NCT05574101 | Cutaneous Squam... Skin Cancer Squamous Cell C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... | Cemiplimab Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | NCT04975152 | Merkel Cell Car... Cutaneous Squam... | Cemiplimab-Rwlc | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Deep sequencIng in Cutaneous Squamous CEll caRciNomas | NCT05878288 | Cutaneous Squam... Cutaneous Squam... Neoplasms Non-melanoma Sk... | Cemiplimab | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | NCT04616248 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... Unresectable Br... Metastatic Mela... Unresectable Me... Cutaneous Squam... Merkel Cell Car... Soft Tissue Sar... Bone Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone | Anti-CD40 Agoni... Poly ICLC Radiation Thera... Recombinant Flt... | 18 Years - | University of Southern California | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03082534 | HNSCC Lip SCC Oral Cavity Can... Oropharynx Canc... Larynx Cancer Hypopharynx Can... Nasopharynx Can... Sinonasal Carci... Cutaneous Squam... Head and Neck N... Head and Neck C... Head and Neck S... | Pembrolizumab, ... | 18 Years - | University of California, San Diego | |
| Dermatoscopy Guided Resection for Skin Cancer | NCT06342297 | Basal Cell Carc... Cutaneous Squam... Surgical Margin | Dermatoscopy | 18 Years - | Region Örebro County | |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | NCT03901573 | Melanoma Merkel Cell Car... Cutaneous Squam... | NT-I7 atezolizumab | 18 Years - | NeoImmuneTech | |
| Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | NCT04252612 | Cutaneous Squam... | Pramlintide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | NCT03684785 | Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... | Cavrotolimod Pembrolizumab Cemiplimab Cavrotolimod | 18 Years - | Exicure, Inc. | |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | NCT06090266 | Cancer Tumor, Solid Malignant Neopl... Metastatic Canc... Advanced Solid ... Platinum-resist... Cutaneous Squam... | OR502 Cemiplimab | 18 Years - | OncoResponse, Inc. | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | NCT05482880 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer High-Risk Cance... Quality of Life Satisfaction, P... | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | NCT04710498 | Cutaneous Squam... | Atezolizumab | 18 Years - | Stanford University | |
| Real World Study on the Use of Cemiplimab in Adult Patients in UK | NCT05493826 | Cutaneous Squam... | No intervention | 18 Years - | Sanofi | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region | NCT05482880 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer High-Risk Cance... Quality of Life Satisfaction, P... | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) | NCT05377905 | Cutaneous Squam... Skin Cancers - ... | Microneedle Arr... | 18 Years - | University of Pittsburgh | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | NCT06270706 | Metastatic Soli... | PLN-101095 Pembrolizumab | 18 Years - | Pliant Therapeutics, Inc. | |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders | NCT05286294 | Melanoma Stage ... Head and Neck S... Cutaneous Squam... MSI-High Clear Cell Rena... Non-small Cell ... | Fecal Microbiot... | 18 Years - | Oslo University Hospital | |
| Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions | NCT04389112 | Cutaneous Squam... Basal Cell Carc... | biopsy | 18 Years - | University Hospital, Bordeaux | |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC | NCT04339062 | Cutaneous Squam... Advanced Cancer | Cemiplimab Everolimus Sirolimus Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT06008977 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Test | 18 Years - | AdventHealth Translational Research Institute | |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC | NCT06046625 | Cutaneous Squam... Cutaneous Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Skin Cancer Patient Satisfa... High-Risk Cance... Preference, Pat... Decision Making Interview | Regular care wi... | 18 Years - | Maastricht University Medical Center | |
| MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer | NCT05076760 | Solid Tumor Advanced Cancer Metastatic Canc... Non Small Cell ... Cutaneous Squam... Merkel Cell Car... Melanoma Pancreatic Canc... Triple Negative... Head and Neck C... | MEM-288 Intratu... Nivolumab | 18 Years - | Memgen, Inc. | |
| A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | NCT05574101 | Cutaneous Squam... Skin Cancer Squamous Cell C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... | Cemiplimab Radiotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cutaneous Squamous Cell Carcinoma Staging Study | NCT05695222 | Cutaneous Squam... | This is not an ... | 18 Years - 120 Years | Queen Mary University of London | |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | NCT04050436 | Cutaneous Squam... Advanced Cutane... Metastatic Cuta... | Cemiplimab RP1 | 18 Years - | Replimune Inc. | |
| Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | NCT05108090 | Squamous Cell C... Nonmelanoma Ski... Cutaneous Squam... | sentinel lymph ... | 18 Years - | Indiana University | |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | NCT03969004 | Cutaneous Squam... | Cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | NCT05220748 | Cutaneous Squam... Head and Neck S... | RM-1995 Pembrolizumab | 18 Years - | Rakuten Medical, Inc. | |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | NCT04916002 | Merkel Cell Car... Cutaneous Squam... Basal Cell Carc... Triple Negative... Non-Small Cell ... Oropharynx Squa... | vidutolimod cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | NCT05888844 | Cutaneous Squam... | INCB099280 | 18 Years - | Incyte Corporation | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies | NCT04349436 | Cutaneous Squam... Merkel Cell Car... Basal Cell Carc... Melanoma | RP1, intra-tumo... | 18 Years - | Replimune Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
